SEC Filing Summary: Immudyne, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Immudyne, Inc. on September 21, 2017, covering events occurring on September 18, 2017. The registrant is a Delaware corporation headquartered in Mount Kisco, NY. Note: The input metadata references "Lifemd, Inc.", but the filing text explicitly identifies the registrant as "Immudyne, Inc."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. Item 9.01 explicitly states "None" regarding financial statements and exhibits.
Material Changes
The primary material change reported is a corporate governance event under Item 5.02:
- Dr. Sven Rohmann voluntarily resigned from the Board of Directors of Immudyne, Inc. on September 18, 2017.
- Dr. Rohmann will continue to serve as the chairman of the company's medical advisory board.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. No unusual items were reported.
Key Facts for Investor Verification
- Confirm the exact date of Dr. Sven Rohmann's resignation from the Board of Directors (September 18, 2017).
- Verify Dr. Rohmann's continued role as chairman of the medical advisory board.
- Check subsequent filings for any impact of this departure on the company's strategic direction or medical oversight.